

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2019-06-12

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2019

GOOD SALES GROWTH DURING MAY; ZINZINO BASED REVENUE INCREASED 21% AND THE TOTAL GROUP REVENUE WITH A TOTAL OF 10% COMPARED WITH THE PREVIOUS YEAR.

The revenue for Zinzino's sales markets increased by 21% to SEK 58.6 (48.3) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 58% and amounted to SEK 3.3 (7.8) million due to high level of internal production during the month. Overall, the Group increased revenues by 10 % to SEK 61.9 (56.1) million compared with the previous year.

Accumulated income January - May increased by 21% to SEK 287.5 (238.5) million compared with the previous year.

Revenues distributed as follows:

Regions, SEK million	19 May	18 May	Change	YTD 2019	YTD 2018	Change
Baltic Markets	4.3	3.9	11%	22.1	17.9	23%
Nordic Markets	31.6	36.0	-12%	154.6	158.4	-2%
Europe Other Markets	20.2	6.6	208%	80.9	26.0	211%
North America	1.9	1.9	2%	9.4	8.2	15%
Australia	0.6	0.0		1.0	0.0	
Zinzino	58.6	48.3	21%	268.0	210.5	27%
Faun Pharma	3.3	7.8	-58%	19.5	28.0	-30%
Zinzino Group	61.9	56.1	10%	287.5	238.5	21%

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information please contact:

Dag Bergheim Pettersen, CEO Zinzino +47 (0) 93 22 57 00
zinzino.com

Pictures for free publication:

Marcus Tollbom +46 (0) 70 190 03 12

Certified Adviser:

Erik Penser Bank Aktiefbolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 16:00 the 12th of June, 2019.

Zinzino AB (publ.) is a direct sales company that operates throughout Europe, North America and Australia Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 34 markets across Europe, North America and Australia. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public company and its shares are listed on Nasdaq First North.